Shanghai Kaibao Pharmaceutical CO.,LTD.  

(Public, SHE:300039)   Watch this stock  
+0.18 (1.18%)
Sep 23 - Close
SHE real-time data - Disclaimer
Currency in CNY
Range 15.13 - 15.49
52 week 11.18 - 15.49
Open 15.28
Vol. 15.08M
Mkt cap 9.56B
P/E 28.89
EPS 0.53
Shares 631.30M

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 24.49% 24.09%
Operating margin 28.01% 26.75%
EBITD margin - 27.09%
Return on average assets 22.20% 19.14%
Return on average equity 24.87% 21.08%
Employees 1,130 -
CDP Score - -


No. 88, Chengpu Road Industrial Comprehensive Developmnt Zone
+86-21-37572069 (Phone)
+86-21-37572069 (Fax)

Website links


Shanghai Kaibao Pharmaceutical CO., LTD. is a China-based company principally engaged in research, development, manufacture and distribution of Chinese medicines. The Company's main products are clear away heat and toxic material injections, which are applied in treatment of upper respiratory tract infections, such as cold and pneumonia; pioglitazone hydrochloride tablets, which are applied in treatment of diabetes; captopril sustained-release tablets, which are adopted in treatment of hypertension, as well as doxofylline capsules, which are applied in treatment of asthma and other diseases. The Company's products mainly include small volume injections, tablets, hard capsules, granules, mixtures, syrup and oral liquids, among others. The Company distributes its products in domestic markets. It also involves in the purchase of agricultural products.

Officers and directors

Yishan Liu Chairman of the Board
Age: 56
Liwang Ren Chief Financial Officer
Age: 43
Guoming Wang General Manager, Director
Age: 50
Jingwei Mu Secretary of the Board, Deputy General Manager
Age: 35
Shaoyong Liu Deputy General Manager, Director
Age: 49
Dongsheng Xue Deputy General Manager, Director
Age: 44
Chongbang Wang Deputy General Manager
Age: 50
Yingjun Zhu Deputy General Manager
Age: 43
Mingwei Feng Director
Age: 43
Laian Mu Director
Age: 59